Dr. Bastholt on Lenvatinib in NSCLC

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer (NSCLC) at the 2016 ESMO Congress.

A phase II study of the agent demonstrated promising clinical activity in a small subset of patients with NSCLC. Approximately 40% of these patients have adenocarcinoma of the lung, and 1% to 2% of those patients have a RET mutation. It is in this specific setting, Bastholt explains, that lenvatinib has demonstrated significant outcomes.

Despite some manageable toxicities associated with this agent, these efficacious results provide support for further study of lenvatinib for RET-positive adenocarcinoma of the lung.